Hoth Therapeutics Announces $2.0 Million Registered Direct Offering

Got story updates? Submit your updates here. ›

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced that it has entered into a definitive agreement for the purchase and sale of 2,857,144 shares of its common stock (or common stock equivalents) at an offering price of $0.70 per share, in a registered direct offering. The company also issued and sold unregistered warrants to purchase up to an aggregate of 2,857,144 shares of common stock at an exercise price of $0.85 per share in a concurrent private placement. The aggregate gross proceeds to the company from the offering are expected to be approximately $2.0 million, before deducting the placement agent's fees and other offering expenses.

Why it matters

This financing will provide Hoth Therapeutics with additional capital to support its clinical-stage biopharmaceutical research and development efforts, as the company continues to focus on developing innovative therapies for unmet medical needs. The registered direct offering and concurrent private placement of warrants demonstrate the company's ability to access the capital markets and secure funding to advance its pipeline.

The details

The shares of common stock (or common stock equivalents) are being offered and sold by the company in a registered direct offering pursuant to a shelf registration statement. The unregistered warrants issued in the concurrent private placement and the shares issuable upon exercise of such warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933. The company intends to use the net proceeds from this offering for general corporate purposes, including working capital.

• The closing of the offering is expected to occur on or about April 2, 2026, subject to the satisfaction of customary closing conditions.
• The unregistered warrants will become exercisable six months following the date of issuance and will expire five and one-half years following the date of issuance.

What’s next

No clear next steps are mentioned in the article. The story focuses on the details of the registered direct offering and concurrent private placement of warrants.